technology
Ginkgo Bioworks to Close Traditional Labs and Spin Off Biosecurity Unit
The Boston company reported cumulative net losses of $6 billion since 2020 and a 24 percent revenue decline last year. It will focus on selling AI-driven lab robots to drug companies and universities while offering cloud access to automated experiments. The company already operates a 50-robot lab in Boston and signed a deal to supply nearly 100 robots to a Department of Energy facility.
May 13, 2:57 PM·2m read1 source
prnewswire.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Ginkgo Bioworks is closing its traditional non-automated labs, spinning off its biosecurity unit and shifting its business to developing and selling AI-powered laboratory robots. The company has recorded total net losses of $6 billion since 2020. Revenue from its synthetic biology services unit fell 24 percent last year to $133 million, less than one-eighth of the amount forecast when the company went public in 2021.
The synthetic biology services business has declined for three straight years. Higher interest rates reduced life sciences funding and increased competition from China contributed to the downturn, particularly in the Boston area. The company has already cut hundreds of jobs and its stock price has fallen more than 95 percent from a peak valuation of $20 billion in 2021.
The company maintains a 50-robot automated lab at its Seaport offices in Boston.
The company struck a $47 million deal in December to provide almost 100 lab robots to the Department of Energy’s Pacific Northwest National Laboratory. The robots, called Reconfigurable Automation Carts, have wheels and robotic arms and can prepare, cultivate and measure thousands of samples.
The company plans to sell access to its automated lab over the cloud to smaller companies and individual scientists for as little as $39 per experiment. Larger fully automated systems will be sold to big drug companies and universities. The company has existing agreements with OpenAI and Google to develop AI and cloud systems for biotech research.
